ReviewCell communication and signaling : CCS2022
Concanavalin A as a promising lectin-based anti-cancer agent: the molecular mechanisms and therapeutic potential.
Review in Cell communication and signaling : CCS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 78 citations in OpenAlex.
- Comprehensive Insights into Plant-Derived Bioactive Peptides: Sources, Technological Strategies, and Health Implications.Molecules (Basel, Switzerland) · 2026Review
- AdultBiomolecules · 2026Article
- Investigating the Antioxidant and Immunomodulatory Effects of Quercetin Using Porcine PBMCs as an Inflammatory In Vitro Model.Antioxidants (Basel, Switzerland) · 2026Article
- A novel anti-CD20, concabody, enhances immunotherapy efficacy by targeting MPZL1 and augmenting antibody-induced cell death.Frontiers in oncology · 2026Article
- Applications of Plant Lectins in Detection and Targeted Therapy of Urological Cancers.Drug design, development and therapy · 2026Review
- Antitumor effects of a lectin purified fromFrontiers in oncology · 2026Article
- Article
- Role of Fruit-Derived Antioxidants in Fighting Cancer: A Narrative Review.Indian journal of clinical biochemistry : IJCB · 2025Review
- Photocatalytic effect of gold-zinc oxide composite nanostructures for the selective and controlled killing of antibiotic-resistant bacteria and the removal of resistant bacterial biofilms from the body.Nano convergence · 2025Article
- Assembly and Functionality of 2D Protein Arrays.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Lectin: A Molecular Tool in Cancer Diagnosis and Therapy with Special Reference to Reproductive Cancers.Molecular biotechnology · 2025Review
- Modelling innate and adaptive immune responses in whole blood: A modifiedJournal of biological methods · 2025Article
- Synthetic 1,3,6-Tri-O-Galloyl-α-D-Glucose Mimics the Hippo Pathway Inhibitor VT107 in Suppressing Concanavalin A-Induced Inflammation in Human Glioblastoma Cells.Journal of inflammation research · 2025Article
- The Promising Role of Plant-Derived Lectins in Oral Cancer Therapeutics: A Systematic Review.Cureus · 2024Review
- Antibacterial and anticancer activities of three novel lectin-conjugated chitosan nanoparticles.Applied microbiology and biotechnology · 2024Article
- Concanavalin A Delivers a Photoactive Protein to the Bacterial Wall.International journal of molecular sciences · 2024Article
- Recent Insights into Glucose-Responsive Concanavalin A-Based Smart Hydrogels for Controlled Insulin Delivery.Gels (Basel, Switzerland) · 2024Review
- Harmful Free Radicals in Aging: A Narrative Review of Their Detrimental Effects on Health.Indian journal of clinical biochemistry : IJCB · 2024Review
- Article
- Understanding the Mode of Action of a Micro-Immunotherapy Formulation: Pre-Clinical Evidence from the Study of 2LEBVLife (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 11 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concanavalin A (ConA), the most studied plant lectin, has been known as a potent anti-neoplastic agent for a long time. Since initial reports on its capacity to kill cancer cells, much attention has been devoted to unveiling the lectin's exact molecular mechanism. It has been revealed that ConA can bind to several receptors on cancerous and normal cells and modulate the related signaling cascades. The most studied host receptor for ConA is MT1-MMP, responsible for most of the lectin's modulations, ranging from activating immune cells to killing tumor cells. In this study, in addition to studying the effect of ConA on signaling and immune cell function, we will focus on the most up-to-date advancements that unraveled the molecular mechanisms by which ConA can induce autophagy and apoptosis in various cancer cell types, where it has been found that P73 and JAK/STAT3 are the leading players. Moreover, we further discuss the main signaling molecules causing liver injury as the most significant side effect of the lectin injection. Altogether, these findings may shed light on the complex signaling pathways controlling the diverse responses created via ConA treatment, thereby modulating these complex networks to create more potent lectin-based cancer therapy. Video Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.